Business
Perimeter Medical Imaging AI to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Perimeter Medical Imaging AI to Participate in the 2026 Bloom Burton & Co. Healthcare Investo...
About this update from Perimeter Medical Imaging Ai Inc
[{"type":"text","content":"\n\n\nPerimeter Medical Imaging AI to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\nPerimeter Medical Imaging AI to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference\nCanada NewsWire\n\n\nTORONTO and DALLAS, April 14, 2026 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) (\"Perimeter\" or the \"Company\"), a commercial-stage medical technology company, is pleased to announce that management will present an update on the Company's business at the 2026 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 21, 2026 at 10:00 a.m. Eastern Time at the Metro Toronto Convention Centre.The presentation will also be broadcast live and archived on the Company's website under \"News/Events\" in the Investors section.About Perimeter Medical Imaging AI, Inc. Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Claire™, recently approved by the U.S. Food and Drug Administration (FDA), is our next-generation AI-enabled device. The Company's ticker symbol \"PINK\" is a reference to the pink ribbons used during Breast Cancer Awareness Month.Indications for Use: The Claire OCT System is an adjunctive three-dimensional imaging tool which provides volumetric cross-sectional, real-time depth visualization, coupled with an artificial intelligence computer-aided detection algorithm which identifies and marks focal areas suspicious for breast cancer. It is used concurrently with physician interpretation of the images. The Claire OCT System is intended for use in conjunction with other standard methods for evaluation of the margins of excised lumpectomy tissue during surgical procedures in patients with a biopsy-confirmed diagnosis of breast cancer.The Claire OCT System should not be used to replace standard tissue histopatholo...